Money Info September 27, 2012

Money Info

INVESTMENT NEWS SHOW

SEPTEMBER 27, 2012

Thursdays 6:05 PM To 7:00 PM EDT

 

Use this Listen Live Link To Watch The Next Show:

http://www.ustream.tv/channel/wpsl-the-talk-of-the-treasure-coast%21

The Princeton Research Money info show features where to invest now, stock market, business, economy and financial investment news. Money Info is hosted by Mike King, Charles Moskowitz and Oscar Carboni.

Tonight’s show will feature:

Cleveland BioLabs, Inc. (Nasdaq:CBLI) a clinical-stage biotechnology company with a focus on oncology and orphan drug development.

See the corporate website: http://www.cbiolabs.com/

CBLI Stock Quote and Trading Charts – Click Here

Recent CBLI News – Click Here

Since its inception in 2003, CBLI has pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Presently, CBLI has nine product candidates in its pipeline that are being developed directly by CBLI and its majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc.

 

CBLI’s most developed drug candidate, CBLB502 (Entolimod™) is being developed for dual indications under the FDA’s Animal Efficacy Rule as a radiation countermeasure, and under the FDA’s traditional drug approval pathway as a cancer therapy and oncology supportive care agent. CBLI anticipates that upon licensure as a radiation countermeasure, Entolimod™ will be sold to the U.S. government for the national stockpile and other defense-related purposes, allied foreign governments and the nuclear energy industry; and upon licensure as a cancer treatment, will be sold to the public through traditional distribution channels.

 

Neil Lyons, CPA, has served as CBLI’s Chief Financial officer since 2011. Neil has over 20 years of financial executive experience, including seven years in life sciences. He has also managed complex Federal contracting operations in excess of $300 million, annually.